NETSOL Technologies Reports Third Quarter Fiscal 2025 Results

1 day ago

Total net revenues for Q3’25 increased by 13%, reaching $17.5 million, when compared with Q3’24.Total service revenue increased 24% in…

Blum Holdings Inc. Reports First Quarter 2025 Financial Results

1 day ago

Revenue Growth of 26% Year-over-Year, EBITDA Turns Positive Amid Operating Improvements and Streamlined Cost Structure, Net Loss Reduced by Over…

Landsbankinn hf.: Correction – Covered bond exchange offering results – Published: 2025-05-14 14:04:01 CEST

1 day ago

Correction: Price, amount and settlement date corrected. In relation to Landsbankinn’s covered bond auction yesterday, was a covered bond exchange…

Rias A/S – Half-Year Report

1 day ago

Half-Year Report - RIAS A/S   Attachment Half-Year report for RIAS signed 2025-05-14

Antalpha Announces Pricing of Initial Public Offering

1 day ago

SINGAPORE, May 14, 2025 (GLOBE NEWSWIRE) -- Antalpha Platform Holding Company (“Antalpha” or the “Company”) today announced the pricing of…

IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights

1 day ago

Primary endpoint of pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine in patients with advanced melanoma still…

KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update

1 day ago

-- Ongoing patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data anticipated…

FlexiHeat UK and Digitaleer Join Forces to Improve FlexiHeats Visibility Online

1 day ago

Three Legged Cross, Dorset, May 14, 2025 (GLOBE NEWSWIRE) -- FlexiHeat UK, a leading provider of high-efficiency heating solutions, is…

ComfoRest Launches New UK Website Selling a Range Ottoman and Divan Beds

1 day ago

Cleckheaton, West Yorkshire, May 14, 2025 (GLOBE NEWSWIRE) -- ComfoRest, a leading bed company offering customers a range of high-quality,…

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update

1 day ago

ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2…

This website uses cookies.